Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases

被引：1

作者：

Hirose, Suguru ^{[1
]}

Enami, Chiaki ^{[1
]}

Kawamatsu, Natsumi ^{[2
]}

Ito, Yoshimi ^{[1
]}

Onoda, Tsubasa ^{[1
]}

Sugiyama, Yutaro ^{[1
]}

Suzuki, Hirosumi ^{[1
]}

Nagafuchi, Miho ^{[1
]}

Ikeda, Takafumi ^{[1
]}

Niisato, Yusuke ^{[1
]}

Yamada, Takeshi ^{[1
]}

Yamamoto, Yoshiyuki ^{[1
]}

Moriwaki, Toshikazu ^{[1
]}

Suzuki, Hideo ^{[1
]}

机构：

[1] Univ Tsukuba, Fac Med, Dept Gastroenterol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan

[2] Univ Tsukuba Hosp, Dept Pathol, Tsukuba, Ibaraki, Japan

来源：

INTERNATIONAL CANCER CONFERENCE JOURNAL | 2022年 / 11卷 / 01期

关键词：

Anti-epidermal growth factor receptor antibody; Appendiceal carcinoma; RAS status; Signet-ring cell carcinoma; Systemic chemotherapy; METASTATIC COLORECTAL-CANCER; THYMIDYLATE SYNTHASE; OXALIPLATIN; SURVIVAL; FLUOROURACIL; ADENOCARCINOMA; COMBINATION; LEUCOVORIN; MUTATIONS; ERCC1;

D O I：

10.1007/s13691-021-00507-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The effect of anti-epidermal growth factor receptor (EGFR) antibody-containing chemotherapy on appendiceal signet-ring cell carcinoma (SRCC) remains unknown. Herein, we report three patients, diagnosed as having synchronous metastases, who underwent this treatment for unresectable appendiceal SRCC with RAS wild type. Cases 1, 2, and 3 received FOLFOX with panitumumab, FOLFOX with cetuximab, and FOLFIRI with cetuximab, respectively, and their progression-free survival were 6.2, 7.2, and 18.7 months, respectively. The subsequent anti-vascular endothelial growth factor antibody-containing therapy was ineffective, and their overall survival was 8.2, 11.4, and 22.9 months, respectively. The anti-EGFR antibody-containing chemotherapy showed moderate efficacy for appendiceal SRCC. Further studies including molecular analysis should be needed.

引用

页码：17 / 22

页数：6

共 35 条

[1] Genomic Landscape of Appendiceal Neoplasms [J].

Ang, Celina S-P ;

Shen, John Paul ;

Hardy-Abeloos, Camille J. ;

Huang, Justin K. ;

Ross, Jeffrey S. ;

Miller, Vincent A. ;

Jacobs, Miriam T. ;

Chen, Ingrid L. ;

Xu, David ;

Ali, Siraj M. ;

Baumgartner, Joel ;

Lowy, Andrew ;

Fanta, Paul ;

Ideker, Trey ;

Millis, Sherri Z. ;

Harismendy, Olivier .

JCO PRECISION ONCOLOGY, 2018, 2 :1-18

[2] Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis [J].

Borazanci, Erkut ;

Millis, Sherri Z. ;

Kimbrough, Jeffery ;

Doll, Nancy ;

Von Hoff, Daniel ;

Ramanathan, Ramesh K. .

JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (01) :164-172

[3] Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer [J].

Chen Shaojun ;

Hua Li ;

Huang Haixin ;

Li Guisheng .

CANCER BIOLOGY & THERAPY, 2018, 19 (03) :153-159

[4] Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms [J].

Choe, J. H. ;

Overman, M. J. ;

Fournier, K. F. ;

Royal, R. E. ;

Ohinata, A. ;

Rafeeq, S. ;

Beaty, K. ;

Phillips, J. K. ;

Wolff, R. A. ;

Mansfield, P. F. ;

Eng, C. .

ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (08) :2578-2584

[5] Appendiceal tumors - Retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies [J].

Connor, SJ ;

Hanna, GB ;

Frizelle, FA .

DISEASES OF THE COLON & RECTUM, 1998, 41 (01) :75-80

[6] Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer [J].

Cremolini, Chiara ;

Antoniotti, Carlotta ;

Stein, Alexander ;

Bendell, Johanna ;

Gruenberger, Thomas ;

Rossini, Daniele ;

Masi, Gianluca ;

Ongaro, Elena ;

Hurwitz, Herbert ;

Falcone, Alfredo ;

Schmoll, Hans-Joachim ;

Di Maio, Massimo .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (28) :3314-3324

[7] Systematic Review: Anti-Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer [J].

Dahabreh, Issa J. ;

Terasawa, Teruhiko ;

Castaldi, Peter J. ;

Trikalinos, Thomas A. .

ANNALS OF INTERNAL MEDICINE, 2011, 154 (01) :37-U180

[8] Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer [J].

Douillard, Jean-Yves ;

Oliner, Kelly S. ;

Siena, Salvatore ;

Tabernero, Josep ;

Burkes, Ronald ;

Barugel, Mario ;

Humblet, Yves ;

Bodoky, Gyorgy ;

Cunningham, David ;

Jassem, Jacek ;

Rivera, Fernando ;

Kocakova, Ilona ;

Ruff, Paul ;

Blasinska-Morawiec, Maria ;

Smakal, Martin ;

Canon, Jean Luc ;

Rother, Mark ;

Williams, Richard ;

Rong, Alan ;

Wiezorek, Jeffrey ;

Sidhu, Roger ;

Patterson, Scott D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11) :1023-1034

[9] Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study [J].

Douillard, Jean-Yves ;

Siena, Salvatore ;

Cassidy, James ;

Tabernero, Josep ;

Burkes, Ronald ;

Barugel, Mario ;

Humblet, Yves ;

Bodoky, Gyoergy ;

Cunningham, David ;

Jassem, Jacek ;

Rivera, Fernando ;

Kocakova, Ilona ;

Ruff, Paul ;

Blasinska-Morawiec, Maria ;

Smakal, Martin ;

Canon, Jean-Luc ;

Rother, Mark ;

Oliner, Kelly S. ;

Wolf, Michael ;

Gansert, Jennifer .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4697-4705

[10] Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial [J].

Glockzin, Gabriel ;

Zeman, Florian ;

Croner, Roland S. ;

Koenigsrainer, Alfred ;

Pelz, Joerg ;

Strohlein, Michael A. ;

Rau, Beate ;

Arnold, Dirk ;

Koller, Michael ;

Schlitt, Hans J. ;

Piso, Pompiliu .

CLINICAL COLORECTAL CANCER, 2018, 17 (04) :285-296

← 1 2 3 4 →